CLAIMS

1. A pyrazolone compound represented by the formula (1)



Formula (1)

wherein A is a C_{2-14} aryl group (the C_{2-14} aryl group may be optionally substituted with one or more C_{1-6} alkyl groups, one or more C_{1-3} alkyl groups substituted with one or more fluorine atoms, one or more halogen atoms, one or more nitro groups, one or more C_{1-6} alkylcarbonyl groups, one or more hydroxyl groups or one or more amino groups (the hydroxyl group and the amino group may be substituted with a C_{1-6} alkyl group or a C_{1-6} alkylcarbonyl group)), B is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, D is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, and E is a C_{2-14} aryl group (the C_{2-14} aryl group is optionally substituted with one or more hydroxyl groups, one or more nitro groups, one or more halogen atoms, one or more cyano groups, one or more C_{1-3} alkyl groups substituted with one or more fluorine atoms, NG^1G^2 (wherein G^1 and G^2 are independently hydrogen atoms, formyl groups, C_{1-6} alkyl groups or C_{1-6}

alkylcarbonyl groups), one or more carboxyl groups, one or more sulfonic acid groups, one or more phosphonic acid groups, one or more carbamido groups (the carbamido group may be substituted with a C_{1-6} alkyl group), one or more sulfamido groups (the sulfamido group may be substituted with a C_{1-6} alkyl group), one or more hydroxycarbamido groups, one or more hydroxysulfamido groups, one or more tetrazole groups, one or more C_{1-6} alkoxycarbonyl groups or $X(CYZ)_nCO_2H$ (wherein X is CH_2, O, S or NG^3 (G^3 is a hydrogen atom, a C_{1-6} alkyl group, a formyl group or a C_{1-6} alkylcarbonyl group), Y and Z are independently hydrogen atoms or C_{1-3} alkyl groups, and n is 0, 1, 2 or 3)), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

2. A pyrazolone compound represented by the formula (2)



Formula (2)

wherein R^1 is a C_{2-14} aryl group (the C_{2-14} aryl group may be optionally substituted with one or more C_{1-6} alkyl groups, one or more C_{1-3} alkyl groups substituted with one or more fluorine atoms, one or more halogen atoms, one or more nitro groups, one or more C_{1-6} alkylcarbonyl groups, one or more hydroxyl groups or one or more amino groups

(the hydroxyl group and the amino group may be substituted with a C_{1-6} alkyl group or a C_{1-6} alkylcarbonyl group)), R^2 is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, R^3 is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, and R^4 is a C_{2-14} aryl group (the C_{2-14} aryl group is optionally substituted with one or more hydroxyl groups, one or more nitro groups or NR^5R^6 (wherein R^5 and R^6 are independently hydrogen atoms, formyl groups, C_{1-6} alkyl groups or C_{1-6} alkylcarbonyl groups)), a tautomer prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

3. The pyrazolone compound according to Claim 2, wherein R^4 is a C_{2-14} aryl group substituted with one or more hydroxyl groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

4. The pyrazolone compound according to Claim 2, wherein R^4 is a C_{2-14} aryl group substituted with NR^5R^6 (wherein R^5 and R^6 are independently hydrogen atoms, formyl groups, C_{1-6} alkyl groups or C_{1-6} alkylcarbonyl groups), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

5. The pyrazolone compound according to Claim 2, wherein R^4 is a C_{2-14} aryl group substituted with one or more nitro groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

6. A pyrazolone compound represented by the formula (3)



Formula (3)

wherein R^7 is a C_{2-14} aryl group (the C_{2-14} aryl group may be optionally substituted with one or more C_{1-6} alkyl groups, one or more C_{1-3} alkyl groups substituted with one or more fluorine atoms, one or more halogen atoms, one or more nitro groups, one or more C_{1-6} alkylcarbonyl groups, one or more hydroxyl groups or one or more amino groups (the hydroxyl group and the amino group may be substituted with a C_{1-6} alkyl group or a C_{1-6} alkylcarbonyl group)), R^8 is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, R^9 is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, and R^{10} is a C_{2-14} aryl group (the C_{2-14} aryl group is optionally substituted with one or more carboxyl groups, one or more sulfonic acid groups, one or more phosphonic acid groups, one or more carbamido groups, one or more sulfamido groups, one or more hydroxycarbamido groups, one or more hydroxysulfamido groups, one or more tetrazole groups,

one or more C_{1-6} alkoxycarbonyl groups or $X(CYZ)_nCO_2H$ (wherein X is CH_2, O, S or NR^{11} (R^{11} is a hydrogen atom, a C_{1-6} alkyl group, a formyl group or a C_{1-6} alkylcarbonyl group), Y and Z are independently hydrogen atoms or C_{1-3} alkyl groups, and n is 0, 1, 2 or 3)), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

7. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more carboxyl groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound, or a solvate thereof.

8. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with $X(CYZ)_nCO_2H$ (wherein X is CH_2, O, S or NR^{11} (R^{11} is a hydrogen atom, a C_{1-6} alkyl group, a formyl group or a C_{1-6} alkylcarbonyl group), Y and Z are independently hydrogen atoms or C_{1-3} alkyl groups, and n is 0, 1, 2 or 3), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

9. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more sulfonic acid groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

10. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more phosphonic acid groups, a tautomer, prodrug or

pharmaceutically acceptable salt of the compound or a solvate thereof.

11. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more tetrazole groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

12. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more carbamido groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

13. The pyrazolone compound according to Claim 6, wherein R^{10} is a C_{2-14} aryl group substituted with one or more sulfamido groups, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

14. A pyrazolone compound represented by the formula (4)



Formula (4)

wherein R^{12} is a C_{2-14} aryl group (the C_{2-14} aryl group may be optionally substituted with one or more C_{1-6} alkyl groups, one or more C_{1-3} alkyl groups substituted with one or more fluorine atoms, one or more halogen atoms, one or more nitro groups, one or more C_{1-6} alkylcarbonyl groups, one or more hydroxyl groups or one or more amino groups

(the hydroxyl group and the amino group may be substituted with a C_{1-6} alkyl group or a C_{1-6} alkylcarbonyl group)), R^{13} is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, R^{14} is a hydrogen atom, a C_{1-6} alkyl group, a C_{1-3} alkyl group substituted with one or more fluorine atoms or a C_{2-14} aryl group, and R^{15} is a C_{2-14} aryl group (the C_{2-14} aryl group is substituted with a substituent selected from a hydroxyl group, an amino group, a nitro group, a halogen atom, a cyano group, a C_{1-3} alkyl group substituted with one or more fluorine atoms, a carbamido group and a sulfamido group (the carbamido group and the sulfamido group may be substituted with a C_{1-6} alkyl group) and with a substituent selected from a carboxyl group, a sulfonic acid group, a phosphonic acid group, a carbamido group, a sulfamido group, a hydroxycarbamido group, a hydroxysulfamido group, a tetrazole group, a C_{1-6} alkoxycarbonyl group and $X(CYZ)_nCO_2H$ (wherein X is CH_2, O, S or NR^{16} (R^{16} is a hydrogen atom, a C_{1-6} alkyl group, a formyl group or a C_{1-6} alkylcarbonyl group), Y and Z are independently hydrogen atoms or C_{1-3} alkyl groups, and n is 0, 1, 2 or 3)), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

15. The pyrazolone compound according to Claim 14, wherein R^{15} is a C_{2-14} aryl group substituted with a

hydroxyl group and a carboxyl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

16. The pyrazolone compound according to Claim 14, wherein R^{15} is a C_{2-14} aryl group substituted with an amino group and a carboxyl group, a tautomer, a prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

17. The pyrazolone compound according to Claim 14, wherein R^{15} is a C_{2-14} aryl group substituted with a substituent selected from a nitro group, a halogen atom, a cyano group, a C_{1-3} alkyl group substituted with one or more fluorine atoms, a carbamido group and a sulfamido group (the carbamido group and the sulfamido group may be substituted with a C_{1-6} alkyl group) and with a carboxyl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

18. The thrombopoietin receptor activator according to Claim 1.

19. The thrombopoietin receptor activator according to Claim 2.

20. The thrombopoietin receptor activator according to Claim 3.

21. The thrombopoietin receptor activator according to Claim 4.

22. The thrombopoietin receptor activator according to Claim 5.

23. The thrombopoietin receptor activator according to Claim 6.

24. The thrombopoietin receptor activator according to Claim 7.

25. The thrombopoietin receptor activator according to Claim 8.

26. The thrombopoietin receptor activator according to Claim 9.

27. The thrombopoietin receptor activator according to Claim 10.

28. The thrombopoietin receptor activator according to Claim 11.

29. The thrombopoietin receptor activator according to Claim 12.

30. The thrombopoietin receptor activator according to Claim 13.

31. The thrombopoietin receptor activator according to Claim 14.

32. The thrombopoietin receptor activator according to Claim 15.

33. The thrombopoietin receptor activator according to Claim 16.

34. The thrombopoietin receptor activator according to Claim 17.

35. A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective, which contains the thrombopoietin

receptor activator according to Claim 18, Claim 19, Claim 20, Claim 21, Claim 22, Claim 23, Claim 24, Claim 25, Claim 26, Claim 27, Claim 28, Claim 29, Claim 30, Claim 31, Claim 32, Claim 33 or Claim 34, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient.

36. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 18, Claim 19, Claim 20, Claim 21, Claim 22, Claim 23, Claim 24, Claim 25, Claim 26, Claim 27, Claim 28, Claim 29, Claim 30, Claim 31, Claim 32, Claim 33 or Claim 34, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient.

37. Medicament comprising at least one compound of formula (1) according to one or more of Claim 1 to 17.